RGNT logo

REGENTIS BIOMATERIALS LTD/IS

RGNTNYSE AMERICAN
🏆 #4892 by market capUS Equity
$1.82▼ $0.15 (−8.08%)
Market closed · at close
🔔
Track RGNT
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 8.1%
7d▼ 11.7%
14d▲ 4.0%
30d▼ 14.6%
ytd▼ 73.2%
1y—
🏦Market Cap
$13M
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
—
Otter Score
80
Good

Trading Snapshot

Day Range
$1.81 – $1.84
52-Week Range
$1.23 – $15.50
Volume
$1.89B
Avg Volume
$1.96B
Shares Outstanding
7.0M
Next Earnings
Nov 2, 2026

Fundamentals Snapshot

Annual Revenue
$2M
Last Q Revenue
$654,718
P/E Ratio
—
P/S Ratio
—
EPS (TTM)
—
Dividend Yield
—

Why Investors Own RGNT

  • ✓High-growth profile — revenue up +33.0% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 38% gross margin and 19% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

RGNT logo

REGENTIS BIOMATERIALS LTD/IS

RGNT
Financial Trends
Revenue (TTM)The total money the company brought in from sales, before subtracting any costs.
$2M▲ +32.3% YoY
Gross Margin (TTM)Of every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
38.2%▲ +0.6% YoY
Operating Income (TTM)Profit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$499,505▲ +32.3% YoY
Free Cash Flow (TTM)Cash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$440,322▲ +32.3% YoY
StockOtter · stockotter.space

About REGENTIS BIOMATERIALS LTD/IS

Regentis Biomaterials Ltd. is a regenerative medicine firm dedicated to crafting innovative solutions for tissue repair, ultimately aiming to enhance patients' health and overall quality of life. The company's primary product in development is GelrinC, a novel, cell-free, ready-to-use hydrogel designed to be solidified into an implant within the knee. This implant serves to address painful knee injuries and mend articular cartilage damage. Regentis Biomaterials leverages its proprietary Gelrin platform, which employs biodegradable hydrogel implants, to develop orthopedic therapies that facilitate the regeneration of compromised or diseased tissues. The company was established in 2004 and operates from its headquarters in Herzliya, Israel.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Good
80/100

Analyst Price Target

ⓘ
Average Target
$2.31
▲ +27.1% Upside
High Target$2.91
Low Target$1.76
Based on 31 analysts

Latest News & Updates

🚀
CNBC·2h ago

REGENTIS BIOMATERIALS LTD/IS tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
CNBC·5h ago

Analysts lift RGNT price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Barron’s·1d ago

REGENTIS BIOMATERIALS LTD/IS announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.